Table 1.
Questionnaire.
Table 2.
Baseline characteristics.
Table 3.
Side effects.
Fig 1.
Course of the FEV1 in % predicted for all 12 patients.
Time = 0 means start of the Twincer. One of the patients who started with lumacaftor/ivacaftor and the patient on ivacaftor started 1,5 years before start of the Twincer. One patient on lumacaftor/ivacaftor started around the same time as he started with the Twincer, and the last patient on lumacaftor/ivacaftor started 2 years after start of the Twincer.
Table 4.
Mean emitted dose per discharge score at quality control (n = 1036), and frequency per discharge score of all used and returned Twincers (total n = 8544; for discharge score 2–5 than n = 6963).